Sign in
4

Changes in Ownership

ArriVent BioPharma, Inc. Filed Acc 0001104659-25-014164

Options or other derivatives

  • Chief Financial Officer acquired 120,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Kung Winston Chief Financial Officer 2025-02-03 Grant or award · Stock Option (right to buy) +120,000 120,000 D
Loading xslF345X05/tm256714-2_4seq1.xml…